FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1811-1821 October 23, 2008 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

An association of gout with hypertension, diabetes, kidney disease, and cardiovascular disease has been observed since the late 19th century. Early investigators, such as Frederick Mahomed, Alexander Haig, and Nathan Smith Davis, hypothesized that uric acid might be a cause of hypertension or renal disease. In 1897, in his presidential address to the American Medical Association, Dr. Davis wrote, "High arterial tension in gout is due in part to uric acid or other toxic substances in the blood which increase the tonus of the [renal] arterioles."¹ Since agents that lower uric acid levels were not available earlier in Davis's career, . . . [Full Text of this Article]

Uric Acid and Cardiorenal Disease — Cause or Consequence?

Uric Acid and Cardiovascular Disease — A Reappraisal

Hyperuricemic Hypertension

Uric Acid, the Metabolic Syndrome, and Diabetes

Uric Acid and Chronic Kidney Disease

Other Cardiovascular Diseases Associated with Hyperuricemia

Caveats and Future Directions

Source Information

From Baylor College of Medicine, Houston (D.I.F.); Ewha Womans University School of Medicine, Seoul, Korea (D.-H.K.); and the University of Colorado Health Sciences Center, Denver (R.J.J.).

Address reprint requests to Dr. Feig at the Department of Pediatrics, Renal Section, Baylor College of Medicine, Houston, TX 77030, or at dfeig@bcm.tmc.edu.

Related Letters:

Uric Acid and Cardiovascular Risk
Leow M. K., Bueno C., Trivedi N., Parmar M. S., Oh J., Won H. Y., Kang S.-M., Hebert L. A., Rovin B., Feig D. I., Johnson R. J.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:538-541, Jan 29, 2009. Correspondence

This article has been cited by other articles:

• MORCILLO, S., ROJO-MARTINEZ, G., MARTIN-NUNEZ, G. M., GOMEZ-ZUMAQUERO, J. M., GARCIA-FUENTES, E., de ADANA, M. R., de la CRUZ ALMARAZ, M., SORIGUER, F. (2010). Trp64Arg Polymorphism of the ADRB3 Gene Predicts Hyperuricemia Risk in a Population from Southern Spain. The Journal of Rheumatology 37: 417-421 [Abstract] [Full Text]  
• Ernstgard, L., Andersen, M., Dekant, W., Sjogren, B., Johanson, G. (2010). Experimental Exposure to 1,1,1,3,3-Pentafluoropropane (HFC-245fa): Uptake and Disposition in Humans. Toxicol Sci 113: 326-336 [Abstract] [Full Text]  
• Thorens, B., Mueckler, M. (2010). Glucose transporters in the 21st Century. Am. J. Physiol. Endocrinol. Metab. 298: E141-E145 [Abstract] [Full Text]  
• van der Harst, P., Bakker, S. J.L., de Boer, R. A., Wolffenbuttel, B. H.R., Johnson, T., Caulfield, M. J., Navis, G. (2010). Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 19: 387-395 [Abstract] [Full Text]  
• Dinour, D., Gray, N. K., Campbell, S., Shu, X., Sawyer, L., Richardson, W., Rechavi, G., Amariglio, N., Ganon, L., Sela, B.-A., Bahat, H., Goldman, M., Weissgarten, J., Millar, M. R., Wright, A. F., Holtzman, E. J. (2010). Homozygous SLC2A9 Mutations Cause Severe Renal Hypouricemia. J. Am. Soc. Nephrol. 21: 64-72 [Abstract] [Full Text]  
• Laubscher, T., Dumont, Z., Regier, L., Jensen, B. (2009). Taking the stress out of managing gout. cfp 55: 1209-1212 [Full Text]  
• Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., Ito, K., Kusanagi, Y., Chiba, T., Tadokoro, S., Takada, Y., Oikawa, Y., Inoue, H., Suzuki, K., Okada, R., Nishiyama, J., Domoto, H., Watanabe, S., Fujita, M., Morimoto, Y., Naito, M., Nishio, K., Hishida, A., Wakai, K., Asai, Y., Niwa, K., Kamakura, K., Nonoyama, S., Sakurai, Y., Hosoya, T., Kanai, Y., Suzuki, H., Hamajima, N., Shinomiya, N. (2009). Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population. Sci Transl Med 1: 5ra11-5ra11 [Abstract] [Full Text]  
• Zhang, W., Sun, K., Yang, Y., Zhang, H., Hu, F. B., Hui, R. (2009). Plasma Uric Acid and Hypertension in a Chinese Community: Prospective Study and Metaanalysis. Clin. Chem. 55: 2026-2034 [Abstract] [Full Text]  
• Shimada, M., Johnson, R. J., May, W. S. Jr, Lingegowda, V., Sood, P., Nakagawa, T., Van, Q. C., Dass, B., Ejaz, A. A. (2009). A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 24: 2960-2964 [Full Text]  
• Doblado, M., Moley, K. H. (2009). Facilitative glucose transporter 9, a unique hexose and urate transporter. Am. J. Physiol. Endocrinol. Metab. 297: E831-E835 [Abstract] [Full Text]  
• Weir, M. R., Anderson, C. A.M. (2009). Optimal Dietary Strategies for Reducing Incident Hypertension. Hypertension 54: 698-699 [Full Text]  
• Preitner, F., Bonny, O., Laverriere, A., Rotman, S., Firsov, D., Da Costa, A., Metref, S., Thorens, B. (2009). Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. USA 106: 15501-15506 [Abstract] [Full Text]  
• Ahn, S.-Y., Nigam, S. K. (2009). Toward a Systems Level Understanding of Organic Anion and Other Multispecific Drug Transporters: A Remote Sensing and Signaling Hypothesis. Mol. Pharmacol. 76: 481-490 [Abstract] [Full Text]  
• Zoppini, G., Targher, G., Negri, C., Stoico, V., Perrone, F., Muggeo, M., Bonora, E. (2009). Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients. Diabetes Care 32: 1716-1720 [Abstract] [Full Text]  
• Bibert, S., Hess, S. K., Firsov, D., Thorens, B., Geering, K., Horisberger, J.-D., Bonny, O. (2009). Mouse GLUT9: evidences for a urate uniporter. Am. J. Physiol. Renal Physiol. 297: F612-F619 [Abstract] [Full Text]  
• Kosugi, T., Nakayama, T., Heinig, M., Zhang, L., Yuzawa, Y., Sanchez-Lozada, L. G., Roncal, C., Johnson, R. J., Nakagawa, T. (2009). Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. J. Physiol. Renal Physiol. 297: F481-F488 [Abstract] [Full Text]  
• Hermans, M. P., Ahn, S. A., Rousseau, M. F. (2009). Raised natriuretic peptides, Big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia. Diabetes and Vascular Disease Research 6: 190-193 [Abstract]  
• Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J., Parving, H.-H. (2009). Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study. Diabetes 58: 1668-1671 [Abstract] [Full Text]  
• Peti-Peterdi, J., Toma, I., Sipos, A., Vargas, S. L. (2009). Multiphoton Imaging of Renal Regulatory Mechanisms. Physiology 24: 88-96 [Abstract] [Full Text]  
• Ding, K., Kullo, I. J. (2009). Genome-Wide Association Studies for Atherosclerotic Vascular Disease and Its Risk Factors. Circ Cardiovasc Genet 2: 63-72 [Full Text]  
• Johnson, R. J., Perez-Pozo, S. E., Sautin, Y. Y., Manitius, J., Sanchez-Lozada, L. G., Feig, D. I., Shafiu, M., Segal, M., Glassock, R. J., Shimada, M., Roncal, C., Nakagawa, T. (2009). Hypothesis: Could Excessive Fructose Intake and Uric Acid Cause Type 2 Diabetes?. Endocr. Rev. 30: 96-116 [Abstract] [Full Text]  
• Leow, M. K., Bueno, C., Trivedi, N., Parmar, M. S., Oh, J., Won, H. Y., Kang, S.-M., Hebert, L. A., Rovin, B., Feig, D. I., Johnson, R. J. (2009). Uric Acid and Cardiovascular Risk. NEJM 360: 538-541 [Full Text]